Drug intelligence / Profile preview

purified chick embryo cell rabies vaccine + human rabies immunoglobulin

Development stage
Phase 3
Lead developer
Bavarian Nordic
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Local Infiltration
01

Overview

This is a **combination therapy** used for post-exposure prophylaxis (PEP) against rabies in humans. It consists of: - **Purified chick embryo cell rabies vaccine (PCECV)**: an inactivated vaccine produced by propagating rabies virus in chick embryo fibroblast cells, then inactivating the virus with β-propiolactone. Administered to generate active immunity by inducing anti-rabies neutralizing antibodies in the recipient[1][3][7]. - **Human rabies immunoglobulin (HRIG)**: derived from pooled human plasma from vaccinated donors, providing immediate, passive anti-rabies antibodies at the exposure site and systemically. HRIG neutralizes the virus until the body produces effective antibodies in response to the vaccine[2][6][7]. Together, these agents are standard of care for PEP after potential rabies exposure (especially **category III exposures** such as bites or scratches that break the skin)[2][6][7]. The recombinant vaccine component is given intramuscularly, while HRIG is administered by infiltration around the wound and any remainder intramuscularly at a distant site. This combination is not for prior immunization but for emergency PEP.

Brand names
RabipurVaxiRab NKEDRAB
Other names
purified chick embryo cell culture rabies vaccine + human rabies immune globulinPCECV + HRIGchick embryo cell rabies vaccine + HRIGchick embryo cell culture rabies vaccine + HRIG
02

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on purified chick embryo cell rabies vaccine + human rabies immunoglobulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on purified chick embryo cell rabies vaccine + human rabies immunoglobulin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call